Add like
Add dislike
Add to saved papers

A descriptive case series of the relationship between maintenance over time of conservative PK/PD efficacy thresholds of dalbavancin and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.

OBJECTIVE: To describe the relationship between maintenance over time of pharmacokinetic/pharmacodynamic (PK/PD) dalbavancin efficacy thresholds and clinical outcome in a case series of patients who underwent therapeutic drug monitoring (TDM) during long-term treatment of staphylococcal osteoarticular infections (OIs).

METHODS: Patients who received two 1500 mg dalbavancin doses one week apart for documented staphylococcal OIs, underwent TDM assessment, and had clinical outcome assessable at follow-up were retrospectively included. Dalbavancin concentrations ≥4.02 and/or ≥8.04 mg/L were identified as conservative PK/PD efficacy thresholds. The percentage of time of the overall treatment period with dalbavancin concentrations above these efficacy thresholds was calculated and correlated with clinical outcome.

RESULTS: A total of 17 patients were retrieved. Long-term dalbavancin was used mainly for treating prosthetic joint infections (9/17; 52.9%). In 13/17 patients (76.5%), clinical outcome was assessable after at least 6-month follow-up and was always successful (100.0%). In 4/17 (23.5%) patients, clinical outcome is going favourably after a follow-up of 3.7, 4.8, 5.1 and 5.3 months, respectively. In most patients, both dalbavancin PK/PD efficacy thresholds were granted for most of treatment duration (%time ≥4.02 mg/L: 100% in 13 cases, 75-99.9% in 2 cases, 50-74.99% in other 2; %time ≥8.04 mg/L: 100% in 8 cases, 75-99.9% in 4 cases, 50-74.99% in other 4, and < 50% in 1 case).

CONCLUSIONS: Our findings could support the idea that maintenance of conservative PK/PD efficacy thresholds of dalbavancin for most of treatment duration may represent a valuable approach in dealing efficaciously with long-term treatment of staphylococcal OIs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app